2026– date –
-
Bristol Myers Squibb’s First CELMoD Therapy ZENBEXUS™ (iberdomide) Receives FDA Accelerated Approval in Combination with Daratumumab for Multiple Myeloma Patients with Early Relapse
Bristol Myers Squibb (Press Release) USA Overview Bristol Myers Squibb announced that its innovative CELMoD therapy, ZENBEXUS™ (iberdomide), received accelerated approval from the U.S. FDA for multiple myeloma, in combination with daratu... -
City of Hope Reports Groundbreaking Phase 1 Data for CD19 CAR T-Cell Therapy in High-Risk ALL Patients, Achieving 84% 18-Month Event-Free Survival with Low Toxicity
Evaluate (Oncology Newsletter) USA Overview Researchers at City of Hope presented pivotal Phase 1 data for a CD19 CAR T-cell therapy in acute lymphoblastic leukemia (ALL), demonstrating an impressive 84% 18-month event-free survival rate... -
Keio University Publishes Long-Term Safety Data in Nature Medicine for iPSC-Derived Neural Stem Cell Transplant in Spinal Cord Injury: No Tumor Formation or Serious Adverse Events Over Four Years
OmniGenix Japan Overview A research team at Keio University has published groundbreaking long-term safety data in Nature Medicine from the world's first clinical study of iPSC-derived neural stem cell transplantation for spinal cord inju... -
Japan Marks 20th Anniversary of iPSC Discovery with World’s First Regenerative Medicine Product Approvals: Myocardial Cell Sheets for Severe Heart Failure and Neural Progenitor Cell Transplants for Parkinson’s Disease
Japan Science and Technology Agency (JST) Japan Overview Twenty years after Professor Shinya Yamanaka's discovery of iPS cells at Kyoto University in 2006, Japan achieved a global first with the approval of iPSC-derived regenerative medi... -
Aspen Neuroscience’s Personalized Cell Therapy Sasineprocel (ANPD001) Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Parkinson’s Disease
Longevity.Technology USA Overview Aspen Neuroscience announced that sasineprocel (ANPD001), its personalized cell therapy for Parkinson's disease, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA... -
Century Therapeutics Targets Q4 2026 IND Submission for iPSC-Derived CNTY-813 in Type 1 Diabetes, Advances CAR-iT Cell Therapy CNTY-308 Towards Clinical Trials This Year
Century Therapeutics, Inc. (Press Release) USA Overview Century Therapeutics announced that it has completed its pre-IND meeting with the FDA for CNTY-813, an iPSC-derived cell therapy for Type 1 diabetes, targeting an Investigational Ne... -
Allogene Therapeutics’ Off-the-Shelf CAR-T Cema-cel Achieves 58.3% MRD Negativity in ALPHA3 Phase 2 LBCL Trial, Securing FDA RMAT and Fast Track Designations
Allogene Therapeutics, Inc. (Press Release) USA Overview Allogene Therapeutics announced strong Q2 2026 results, highlighting that its off-the-shelf CAR T-cell therapy, cema-cel, achieved a robust 58.3% minimal residual disease (MRD) neg... -
Autolus Therapeutics Reports 119% YoY Increase in Q2 2026 AUCATZYL® Net Product Sales to $45.7M, Raising Full-Year Guidance and Securing $250M Credit Facility for Extended Runway
Autolus Therapeutics, Inc. (Press Release via GlobeNewswire) USA Overview Autolus Therapeutics announced that its CAR T-cell therapy, AUCATZYL® (obecabtagene autoleucel; obe-cel), generated $45.7 million in net product sales for Q2 2026,... -
Reprogramming the Future: Liv Hospital Details iPSC Therapy’s Transformative Role in Regenerative Medicine
Liv Hospital Turkey Overview Liv Hospital recently published an insightful article on induced pluripotent stem cell (iPSC) therapy, highlighting its profound impact on regenerative medicine, diverse applications, and global clinical prog... -
CRISPR’s Clinical Horizon: Liv Hospital Report Maps 2026 FDA Landscape and Broad Therapeutic Potential
Liv Hospital Turkey Overview Liv Hospital has published a comprehensive review outlining the latest advancements in CRISPR gene-editing technology, emphasizing its revolutionary impact on medical treatments. The report highlights breakth...
